M
Malcolm F. G. Stevens
Researcher at University of Nottingham
Publications - 316
Citations - 13044
Malcolm F. G. Stevens is an academic researcher from University of Nottingham. The author has contributed to research in topics: Temozolomide & Benzothiazole. The author has an hindex of 57, co-authored 315 publications receiving 12291 citations. Previous affiliations of Malcolm F. G. Stevens include Keele University & Hauptman-Woodward Medical Research Institute.
Papers
More filters
Journal ArticleDOI
Structural studies on bio-active compounds. part 2. the solid-state and solution conformations of n-methyl-2-nitroethenamine and related compounds
TL;DR: In this paper, the 1H n.m.r. spectra of NN-dimethyl-2-nitroethenamine, N-methyl-2,nitro-ethenamines, and 2-nitrogen-2.
Journal ArticleDOI
Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
TL;DR: Modifications of potent lipophilic dihydrofolate reductase inhibitors prepared by base-promoted cyclization of the nitrophenylbenzylamino groups had only low growth inhibitory activities but, unlike methylbenzoprim, this activity was unaffected by hypoxanthine/thymidine rescue.
Journal ArticleDOI
Antitumor Benzothiazoles. Part 20. 3′-Cyano and 3′-Alkynyl-Substituted 2-(4′-Aminophenyl)benzothiazoles as New Potent and Selective Analogues.
Ian Hutchinson,Tracey D. Bradshaw,Charles S. Matthews,Malcolm F. G. Stevens,Andrew D. Westwell +4 more
Journal ArticleDOI
Antitumour Polycyclic Acridines. Part 13.1 Synthesis of 2-Substituted 7H-Pyrido[4,3,2-kl]Acridines by Thermolysis of 9-(5-Alkyltriazol-1-yl)Acridines†:
TL;DR: In this article, the interaction of phosphoranylidene ketones with 9-azidoacridine in refluxing benzene affords 9-(5-substituted triazol-1-yl)acridines, which, on thermolysis in boiling diphenyl ether at 259 °C, yield...
Journal ArticleDOI
A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor.
N. S. A. Stuart,S. M. Crawford,G. R. P. Blackledge,Edward S. Newlands,John A. Slack,Richard Hoffman,Malcolm F. G. Stevens +6 more
TL;DR: In view of the lack of anti-folate activity at toxic levels, no phase II trials are currently proposed; toxicological and in vitro studies will continue.